IMV was a clinical-stage biopharmaceutical company based in Halifax, Canada. The company was developing a cancer vaccine based on a proprietary platform for the treatment of both hematological cancers and solid tumors. IMV went public on the NASDAQ in 2021 under the ticker IMV.
Solid tumors
CTI LSF II
Lead
Director
June 6, 2016
Liquidated in 2023
PIPE
IMV had a proprietary novel delivery platform called DPX, which was designed to enhance immune responses for cancer vaccines
May 3, 2018
November 7, 2016
March 29, 2017
